Deutsche Bank
CLDX icon

Deutsche Bank’s Celldex Therapeutics CLDX Stock Holding History

Deutsche Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-30
Closed -$1K – 5428
2013
Q3 		$1K Buy
+30
New +$10.3K ﹤0.01% 5383

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's CLDX Position: Q2 2026 in Review

Deutsche Bank increased its Celldex Therapeutics (CLDX) stake by 23% in Q2 2026, buying an estimated $1.08M and bringing the position to 176,592 shares worth $6.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

Deutsche Bank first reported a position in CLDX in Q2 2013 and has held it in 47 quarters since. The position peaked at $37.7M in Q1 2015. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Deutsche Bank held 176,592 shares of Celldex Therapeutics worth $6.57M as of Q2 2026.
  • Deutsche Bank bought 33,555 Celldex Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Celldex Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1230 holding.
  • Deutsche Bank first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • Deutsche Bank's Celldex Therapeutics position peaked at $37.7M in Q1 2015.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.